Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance

R Choudhary, A K Sharma, R Choudhary, A K Sharma

Abstract

Alarming situation has been caused due to the emergence of COVID-19 infection around the world. There is an urgency of developing a therapeutic strategy in order to control the spread of COVID-19. Towards that initiative, potential drugs like hydroxychloroquine, ivermectin and azithromycin have been tested by diverse group of researchers worldwide for their potential against novel coronavirus. The present report presents together the comprehensive knowledge derived from the major researches about the above drugs altogether in context of the current health emergency around the world. Hydroxychloroquine and ivermectin were known to act by creating the acidic environment and inhibiting the importin (IMPα/β1) mediated viral import. Azithromycin was found to act similar to the hydroxychloroquine as an acidotropic lipophilic weak base. All the three categories of drugs seemed to potentially act against novel coronavirus infection. However, their efficacies need to be studied in detail individually and in combination in-vivo in order to combat COVID-19 infection.

Keywords: Azithromycin; COVID-19; coronavirus; hydroxychloroquine; ivermectin.

© 2020 Published by Elsevier Ltd.

Figures

Fig. 1
Fig. 1
Data obtained from coronavirus resource centre of John Hopkins University of Medicine (1).
Fig. 2
Fig. 2
Illustration showing each drug mode of action against COVID-19 infection.

References

    1. Center J.H.C.R.
    1. Liu J., Cao R., Xu M., Wang X., Zhang H., Hu H. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16.
    1. X Yao, F Ye, M Zhang, C Cui, B Huang, P Niu. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa237. ciaa237.
    1. Gautret P., Lagier J.C., Parola P., Meddeb L., Mailhe M., Doudier B. Hydroxychloroquine and azithromycin as a treatment of COVID19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020:n105949. doi: 10.1016/j.ijantimicag.2020.105949.
    1. Caly L., Druce J.D., Catton M.G., Jans D.A., Wagstaff K.M. The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir Res. 3 April 2020:104787.
    1. Poschet J.F., Perkett E.A., Timmins G.S., Deretic Vojo. Azithromycin and ciprofloxacin have a chloroquine-like effect on respiratory epithelial cells. bioRxiv. 2020;3(29) doi: 10.1101/2020.03.29.008631.
    1. Weniger H. Review of side effects and toxicity of chloroquine. Bull World Health. 1979;79:906.
    1. Fox R.I. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum. 1993;23(2):82–91.
    1. Chang T.H., Wang L.F., Lin Y.S., Yang C.S., Yu C.Y., Lin Y.L. Hydroxychloroquine activates host antiviral innate immunity. Cytokine. 2014;70(1):33–34.
    1. Azeem S., Ashraf M., Rasheed M.A., Anjum A.A., Hameed R. Evaluation of cytotoxicity and antiviral activity of ivermectin against Newcastle disease virus. Pak J Pharm Sci. 2015;28(2):597–602.
    1. Mastrangelo E., Pezzullo M., De Burghgraeve T., Kaptein S., Pastorino B., Dallmeier K. Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug. J Antimicrob Chemother. 2012;67(8):1884–1894. doi: 10.1093/jac/dks147.
    1. Götz V., Magar L., Dornfeld D., Giese S., Pohlmann A., Höper D. Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import. Sci Rep. 2016;6:23138. doi: 10.1038/srep23138.
    1. Lundberg L., Pinkham C., Baer A., Amaya M., Narayanan A., Wagstaff K.M. Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication. Antivir Res. 2013;100(3):662–672.
    1. Jans D.A., Martin A.J., Wagstaff K.M. Inhibitors of nuclear transport. Curr Opin Cell Biol. 2019;58:50–60.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner